Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients
Maria Schwaederlé(AstraZeneca (Japan)), Razelle Kurzrock(Medical College of Wisconsin), Olivier Harismendy(Acadia Pharmaceuticals (United States)), Barbara A. Parker(University of California San Diego), David Piccioni(Center for Personalized Cancer Treatment), Santosh Kesari(Cancer Institute (WIA)), Megumi Ikeda(Center for Personalized Cancer Treatment), Sandip Pravin Patel(University of California San Diego), Richard B. Schwab(Center for Personalized Cancer Treatment), Paul T. Fanta(Center for Personalized Cancer Treatment), Hatim Husain(University of California, San Diego)
Cited by 151
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Deciphering cell–cell interactions and communication from gene expression
|Nature Reviews Genetics|2020|1.3k